Peritia

Executive Summary

Peritia is a global life sciences consulting firm formed in 2019 through the acquisition and integration of several established consulting and service platforms. Headquartered in San Francisco, the company provides strategic and operational support across the biopharmaceutical and medical device industries, with integrated expertise in clinical development, value and evidence generation, and product commercialization. As a private company with no disclosed funding or revenue, Peritia positions itself as a comprehensive partner for life sciences companies navigating complex regulatory and market environments. The firm's consulting-driven model offers resilience in varying market conditions, though its lack of proprietary products or pipeline limits high-growth potential. In the competitive consulting landscape, Peritia's key differentiator is its integrated 'end-to-end' offering, which combines clinical, regulatory, and commercial expertise under one roof. The company is well-positioned to capture demand from biopharma firms seeking to outsource complex functions and reduce costs. However, its growth may be constrained by intense competition from larger players like IQVIA and Accenture. Near-term catalysts could include strategic acquisitions to expand capabilities or geographic reach, as well as new partnerships with emerging biotech companies. Overall, Peritia represents a stable, moderately attractive investment opportunity in the life sciences services sector, with a conviction score of 62.

Upcoming Catalysts (preview)

• Q3 2026Acquisition of a niche regulatory consulting firm to strengthen expertise in gene therapies45% success
• Q4 2026Announcement of a multi-year strategic partnership with a top-20 biopharma company for integrated clinical and commercial services55% success
• Q1 2027Launch of a digital health consulting practice leveraging AI/ML for clinical trial optimization60% success